Sofosbuvir interactions
Full monograph for SofosbuvirCheck it against another medicine
Medicines
62 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amiodarone Hydrochloride | Major | Others | Severe, life-threatening, symptomatic bradycardia has been reported during coadministration of amiodarone with ledipasvir-sofosbuvir or with sofosbuvir taken… | 8 sources — open the full entry |
| Apalutamide | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Carbamazepine | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Enzalutamide | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Fosphenytoin Sodium | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Lorlatinib | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Oxcarbazepine | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Phenobarbital | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Phenytoin Sodium | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Primidone | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Rifampicin | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Rifampicin + Isoniazid | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Acarbose | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Alogliptin Benzoate | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Biphasic Insulin Aspart | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Bromocriptine Mesylate | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Canagliflozin Hemihydrate | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Dapagliflozin Propanediol | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Dulaglutide | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Elacestrant | Moderate | Absorption | Coadministration with elacestrant may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance… | 1 sources — open the full entry |
| Empagliflozin | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Empagliflozin + Linagliptin | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Empagliflozin + Metformin Hydrochloride | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Erdafitinib | Moderate | Distribution | Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Ertugliflozin | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Glibenclamide | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Glimepiride | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Glimepiride + Metformin | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Glipizide | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Glipizide + Metformin Hydrochloride | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Insulin Aspart | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Insulin Aspart + Insulin Aspart Protamine | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Insulin Aspart [Protamine Crystallised] | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Insulin Degludec | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Insulin Degludec + Insulin Aspart Premixed | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Insulin Detemir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Insulin Glargine | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Insulin Glulisine | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Insulin Human [rDNA] | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Insulin Lispro | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Insulin Lispro Protamine + Insulin Lispro | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Lasmiditan Hemisuccinate | Moderate | Distribution | Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer… | 1 sources — open the full entry |
| Linagliptin | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Linagliptin + Metformin Hydrochloride | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Liraglutide | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Metformin Hydrochloride | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Miglitol | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Pioglitazone | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered… | 11 sources — open the full entry |
| Pioglitazone + Glimepiride | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
Conditions
Conditions in which Sofosbuvir needs care, as documented in this source.
IMMUNE SUPPRESSION
MajorHBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive). HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients. All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy. Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.
7 sources
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
- "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences (2014):
- "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC (2022):
- "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):
- "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences (2016):
- "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences (2017):
- "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical (2017):
Hepatic Insufficiency
ModerateSofosbuvir is extensively metabolized in the liver. The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis. No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).
1 source
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
Kidney Diseases
ModerateThe safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis. No dosage recommendation can be given for patients with severe renal impairment or ESRD. No dosage adjustment is necessary for patients with mild or moderate renal impairment.
1 source
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):